Drug Manufacturers – Other
(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug
Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary...
(WCRX) Warner Chilcott Announces Change in Leadership of Research & Development Division
Warner Chilcott (WCRX) recently announced that there will be a change at the helm of its research & development (R&D) division from the beginning of next year. The need for change arose following...
(NVO) Novo Nordisk Presents Diabetes Study Data
Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like...
(SHPGY) Shire to Produce More Replagal
UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved...
(ENDP) Endo Pharmaceuticals Announces FDA Action Date
Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review...
(SHPGY) Shire’s Firazyr Earns FDA Panel Backing
Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant).
Shire...
(RDY) Dr. Reddy’s Laboratories Launches Generic Levaquin
Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Johnson & Johnson’s (JNJ) antibiotic drug,...
(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek
Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England...
(ENDP) Endo Pharmaceuticals Holdings Buys American Medical
Recently, Endo Pharmaceuticals Holdings Inc. (ENDP) completed the purchase of American Medical Systems, a leading pelvic-health device provider, in an all cash deal worth approximately $2.9 billion.
By...
(RDY) Dr. Reddy’s Laboratories Announces FDA Warning Letter
Dr. Reddy’s Laboratories (RDY) recently announced that the US Food and Drug Administration (FDA) issued a four item warning letter regarding the company’s chemical manufacturing facility at Cuernavaca,...
(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses...
(ENDP) Endo Pharmaceuticals Evenly Poised
We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00.
Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare...
(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per...
(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues
Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate...
(ISIS) Isis Pharmaceuticals Reported Loss Widens
Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents.
Revenues...
(VRTX) Vertex Pharmaceuticals Posts Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss...
(CEPH) Cephalon First Quarter 2011 Earnings Miss Expectations
Cephalon Inc. (CEPH) delivered first quarter earnings of $1.98 per share, several cents below the Zacks Consensus Estimate of $2.04 but 12.5% above the year-ago earnings of $1.76.
First quarter revenues,...
(AGN) Company News for May 5, 2011 – Corporate Summary
• R.R. Donnelley & Sons (NYSE:RRD) reported Q1 EPS of $0.33, missing the Zacks Consensus Estimate of $0.36 per share. Revenues for the quarter rose 7% year-over-year to $2.58 billion, lower than the Zacks Consensus...
(GERN) Geron 2011 First Quarter Posts Wider Loss
Geron Corporation (GERN) posted a net loss of 20 cents per share in the first quarter of 2011, wider than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 18 cents. First quarter...
(TEVA) Teva Pharmaceutical Industries Announces Aquisition of Cephalon
Yet another acquisition deal was announced in the pharma sector with generic player, Teva Pharmaceutical Industries Ltd. (TEVA) entering into a definitive agreement with Cephalon, Inc. (
(CEPH) Stock Market News for May 3, 2011 – Market News
Late on Sunday, US President Barack Obama declared: “I determined that we had enough intelligence to take action and authorized an operation to get Osama bin Laden and bring him to justice….After a firefight, they killed Osama bin Laden and took custody of his body.”...
(AMRN) Company News for April 19, 2011 – Corporate Summary
• Amarin’s (NASDAQ:AMRN) share prices sky rocketed 95% after promising results from a new cholesterol drug led to speculation that the company could soon be a takeover target for Big Pharma
• Share prices...
(FRX) Forest Labs Fourth Quarter 2011 Earnings Preview
Forest Labs (FRX) is all set to announce its fourth quarter and fiscal 2011 results on April 19. The Zacks Consensus Estimate for the fourth quarter is $1.07, representing a year-over-year...
(ENDP) Endo Pharmaceuticals Holdings to Take Over American Medical Systems
In a bid to diversify its business and bolster its urology portfolio, Endo Pharmaceuticals Holdings Inc. (ENDP), a US-based specialty healthcare solutions company which develops branded products and specialty...
(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares
We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the...
(SHPGY) Shire and Watson Pharmaceuticals in Patent Legal Battle
The legal tussle between Shire (SHPGY) and Watson Pharmaceuticals Inc. (WPI) intensified with the Ireland based Shire filing a case of...
(AGN) Company News for April 04, 2011 – Corporate Summary
• The Nasdaq OMX Group (NASDAQ:NDAQ) and the IntercontinentalExchange (NYSE:ICE) announced a joint proposal to acquire NYSE Euronext (NYSE:
4Apr2011 | vitalstocks | 0 comments | Continued(ALXA) Alexza Pharmaceuticals – Bull of the Day
We are upgrading our rating on shares of Alexza Pharmaceuticals (ALXA) to Outperform and raising our price target to $3 per share. We believe the company is on track to re-file the new drug application (NDA)...
(VRX) Valeant Pharmaceuticals International’s Sales Benefit Post Merger
Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share....
(MDCO) The Medicines Company Reports Fourth Quarter Earnings Beat
The Medicines Company (MDCO) reported a fourth-quarter profit of 27 cents per share, including the impact of stock-based compensation expense. Fourth quarter profit exceeded the Zacks Consensus Estimate of...